Improving test properties for neonatal cystic fibrosis screening in the Netherlands before the nationwide start by May 1st 2011

Journal of Inherited Metabolic Disease

Volumn 35, Issue 4, 2012, Pages 635-640

  Cornel, Martina C ^a,b,c,g   Gille, Johan J P ^a   Loeber, J Gerard ^d   Vernooij Van Langen, Annette M M ^d,e   Dankert Roelse, Jeannette ^e   Bolhuis, Piet A ^f  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre for Society and Genomics   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e Zuyderland Medical Centre   (Netherlands)

^f Forum Biotechnology and Genetics   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOREACTIVE TRYPSINOGEN; PANCREATITIS ASSOCIATED PROTEIN; TRYPSINOGEN; UNCLASSIFIED DRUG;

CFTR GENE; CONFERENCE PAPER; CYSTIC FIBROSIS; DIAGNOSTIC ACCURACY; DNA SEQUENCE; GENE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH PROGRAM; HETEROZYGOTE; HUMAN; IMMIGRANT; NETHERLANDS; NEWBORN SCREENING; PILOT STUDY; SENSITIVITY AND SPECIFICITY;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC TESTING; HUMANS; INFANT, NEWBORN; MASS SCREENING; MUTATION; NEONATAL SCREENING; NETHERLANDS; PARENTS; PILOT PROJECTS; SENSITIVITY AND SPECIFICITY; SWEAT;

EID: 84863879349     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9452-7     Document Type: Conference Paper

References (15)

1. Achterbergh R, Lakeman P, Stemerding D, Moors EHM, Cornel MC (2007) Implementation of preconceptional carrier screening for cystic fibrosis and haemoglobinopathies: A sociotechnical analysis. Health Policy 83:277-286 (Pubitemid 47259215)
2. Adam BW, Alexander JR, Smith SJ, Chace DH, Loeber JG, Elvers LH, Hannon WH (2000) Recoveries of Phenylalanine from Two Sets of Dried-Blood-Spot Reference Materials: Prediction from Hematocrit, Spot Volume, and Paper Matrix. Clin Chem 46:126-128 (Pubitemid 30090972)
3. Comeau AM, Parad RB, Dorkin HL, Dovey M et al (2004) Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 113:1573-1581 (Pubitemid 38697961)
4. Dagorn JC (2011) CF newborn screening with theMucoPAP kits: Changing the dilution factor. Available from http://isns-neoscreening-org. site-preview.net/htm/news-detail.htm?id=130
5. Dankert-Roelse JE, Te Meerman GJ, Cornel MC, Knol K, Ten Kate LP (1986) Neonatal screening for cystic fibrosis. Lancet 1(8484):802-803 (Pubitemid 16075675)
6. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM (2006) Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 149:362-366 (Pubitemid 44308429)
7. Health Council of the Netherlands. Neonatal Screening. The Hague: Health Council of the Netherlands, 2005; publication no. 2005/11.ISBN 90-5549-572-7. Available from http://www.gezondheidsraad.nl/en/publications/neonatal-screening
8. Health Council of the Netherlands. Neonatal screening for cystic fibrosis. The Hague: Health Council of the Netherlands, 2010; publication no. 2010/01E. ISBN 978-90-5549-817-8 Available from www.gezondheidsraad.nl/en/ publications/neonatal-screening-cystic-fibrosis
9. Lakeman P, Gille JJ, Dankert-Roelse JE et al (2008) CFTR mutations in Turkish and North African cystic fibrosis patients in Europe: implications for screening. Genet Test 12:25-35
10. Sarles J, Berthézène P, Le Louarn C et al (2005) Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 147:302-305 (Pubitemid 41345757)
11. Sommerburg O, Lindner M, Muckenthaler M et al (2010) Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 33(Suppl 2):S263-S271
12. Southern KW, Mérelle MM, Dankert-Roelse JE, Nagelkerke AD (2009) Newborn screening for cystic fibrosis. Cochrane Database Syst Rev. Jan 21;(1):CD001402
13. Ten Kate LP, Feenstra-de Gooyer I, Ploeg-de Groot G, Gouw WL, Anders GJ (1978) Should we screen all newborns for cystic fibrosis? Int J Epidemiol 7:322-330
14. Vernooij-van Langen AMM, Loeber JG, Elvers B et al (2011) Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax Dec 2011 (accepted)
15. Wilcken B, Chalmers G (1985) Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 2(8468):1319-1321 (Pubitemid 16175417)